The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1383
February 6, 2012
View Complete Issue         Table of Contents 2019 
Crizotinib (Xalkori) for Non-Small Cell Lung Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Crizotinib (Xalkori) for Non-Small Cell Lung Cancer
February 6, 2012 (Issue: 1383)
The FDA has approved crizotinib (Xalkori – Pfizer), an oral tyrosine kinase inhibitor, for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with the anaplastic lymphoma kinase (ALK) translocation, which is found in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Crizotinib (Xalkori) for Non-Small Cell Lung Cancer
Article code: 1383c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.